Long-Term Efficacy Demonstrated in ADjoin Study

New data presented by Eli Lilly at the American Academy of Dermatology (AAD) Annual Meeting in Orlando reveal that 50% of patients with moderate-to-severe atopic dermatitis achieved complete skin clearance after three years of maintenance treatment with EBGLYSS (lebrikizumab-lbkz). This monoclonal antibody selectively inhibits IL-13 signaling, a key driver of inflammation in atopic dermatitis.

Among patients responding at Week 16 in earlier monotherapy trials, 87% maintained almost-clear skin at the three-year mark. The ADjoin long-term extension study confirmed sustained reductions in itch, skin pain, and sleep disturbances associated with the condition, significantly improving patients’ quality of life.

Safety Profile and Subgroup Analyses

The safety profile remained consistent with earlier trials, with mild-to-moderate side effects such as conjunctivitis and injection-site reactions. No new safety concerns emerged over the extended treatment period.

Additional analyses in subpopulations with skin of color and patients previously treated with dupilumab showed comparable improvements, emphasizing EBGLYSS’s broad applicability. These findings support EBGLYSS as a versatile option for a diverse patient population.

Clinical and Commercial Significance

EBGLYSS is currently approved in the US as the only first-line monotherapy biologic for moderate-to-severe atopic dermatitis not controlled by topical therapies, with once-monthly maintenance dosing. New insurance coverage agreements announced by Lilly enhance patient access to this therapy, supporting broader treatment adoption.

Dr. Raj Chovatiya, Clinical Associate Professor at Rosalind Franklin University and study investigator, stated, “These three-year results set a new benchmark for durable disease control, helping patients achieve and maintain complete skin clearance.”

Looking Ahead: Ongoing Research and Market Outlook

Eli Lilly plans to continue gathering long-term outcome data and expand studies into additional patient segments. The company also collaborates with Almirall for EBGLYSS commercialization in Europe.

This milestone reinforces Eli Lilly’s growing dermatology portfolio and highlights the promise of targeted IL-13 inhibition for sustained management of atopic dermatitis—a condition affecting millions globally.